David P Dearnaley
Overview
Explore the profile of David P Dearnaley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
7584
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azria D, Haviland J, Brengues M, Griffin C, Moquet J, Barnard S, et al.
Br J Radiol
. 2025 Mar;
PMID: 40080701
Objectives: Radiation-induced lymphocyte apoptosis (RILA) and chromosomal damage assays (CDA) assays are proposed predictors of radiotherapy (RT) adverse events (RTAE). This study evaluated RILA and CDA in patients undergoing different...
2.
Halabi S, Guo S, Roy A, Rydzewska L, Godolphin P, Hussain M, et al.
J Clin Oncol
. 2024 Jun;
42(24):2940-2941.
PMID: 38875510
No abstract available.
3.
Kwak L, Ravi P, Armstrong J, Beckendorf V, Chin J, DAmico A, et al.
J Clin Oncol
. 2024 Mar;
42(18):2132-2138.
PMID: 38471051
Purpose: We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in patients treated with RT alone, RT plus short-term (st;...
4.
Halabi S, Roy A, Rydzewska L, Guo S, Godolphin P, Hussain M, et al.
J Clin Oncol
. 2024 Jan;
42(9):1044-1054.
PMID: 38181323
Purpose: Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC...
5.
Naderi E, Aguado-Barrera M, Schack L, Dorling L, Rattay T, Fachal L, et al.
JNCI Cancer Spectr
. 2023 Oct;
7(6).
PMID: 37862240
Background: This study was designed to identify common genetic susceptibility and shared genetic variants associated with acute radiation-induced toxicity across 4 cancer types (prostate, head and neck, breast, and lung)....
6.
Roy S, Romero T, Michalski J, Feng F, Efstathiou J, Lawton C, et al.
J Clin Oncol
. 2023 Aug;
41(32):5005-5014.
PMID: 37639648
Purpose: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. Materials...
7.
Brand D, Bruningk S, Wilkins A, Naismith O, Gao A, Syndikus I, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
117(5):1163-1173.
PMID: 37433374
Purpose: Rectal dose delivered during prostate radiation therapy is associated with gastrointestinal toxicity. Treatment plans are commonly optimized using rectal dose-volume constraints, often whole-rectum relative-volumes (%). We investigated whether improved...
8.
Attard G, Murphy L, Clarke N, Sachdeva A, Jones C, Hoyle A, et al.
Lancet Oncol
. 2023 May;
24(5):443-456.
PMID: 37142371
Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we...
9.
Ferreira M, Andreyev J, Wedlake L, Dearnaley D
Br J Cancer
. 2023 Jan;
128(5):711-712.
PMID: 36717675
No abstract available.
10.
Brand D, Bruningk S, Wilkins A, Naismith O, Gao A, Syndikus I, et al.
Int J Radiat Oncol Biol Phys
. 2022 Aug;
115(2):327-336.
PMID: 35985457
Purpose: Moderately hypofractionated external beam intensity modulated radiation therapy (RT) for prostate cancer is now standard-of-care. Normal tissue toxicity responses to fraction size alteration are nonlinear: the linear-quadratic model is...